GlassScriptPhysician profile
Anu B Swarup
NPI 1588622021
$1,453.38
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $154 · 2021: $342 · 2022: $196 · 2023: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $403.56 | 2019-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $143.51 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $133.82 | 2019 | |
| Lilly USA, LLC | $126.32 | 2019-2023 | Trulicity, Mounjaro |
| Abbvie INC. | $124.36 | 2020-2023 | Vraylar, Ubrelvy |
| Astellas Pharma US INC | $123.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $85.67 | 2019-2021 | |
| Allergan, INC. | $76.37 | 2019-2020 | |
| Amgen INC. | $41.83 | 2021-2023 | Prolia, Evenity |
| Dexcom, INC. | $39.65 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $34.65 | 2019-2021 | |
| Amarin Pharma, INC. | $29.69 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $29.51 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $18.12 | 2019 | |
| Pfizer INC. | $15.95 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.49 | 2021 | |
| Glaxosmithkline, LLC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Swarup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.